Acura Investors: Why Shares Popped 70%

As the Food and Drug Administration puts increasing amounts of pressure on pharmaceutical companies to release abuse-resistant varieties of their high-abuse-risk drugs, Acura has done just that, and shares are soaring as a result. This is Acura's second abuse-resistant drug, but unlike Oxecta -- its version of oxycodone that is resistant to being crushed up and on which the company receives only milestones and royalties -- its new drug, Nexafed, which is an abuse-resistant form of Sudafed that prevents users from synthesizing methamphetamine from the drug, is wholly owned by Acura and should be even bigger for the company than Oxecta. The company is still down 30% from where it was at the beginning of 2012, but it is profitable and has no debt, which makes it an interesting company to keep an eye on.

See more in the following video.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


The article Acura Investors: Why Shares Popped 70% originally appeared on Fool.com.

David Williamson owns shares of Pfizer. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Investment Strategies

What's your investing game plan?

View Course »

Behavioral Finance

Why do investors make the decisions that they do?

View Course »

Add a Comment

*0 / 3000 Character Maximum